Fox Chase Cancer Center


 

2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunitinib - Which Drug Showed Greater Response in the 1st Line Advanced Disease? Did MK-6482 Show Clinical Activity in Clear Cell Disease?

30 views
June 26, 2020
Comments 0
Login to view comments. Click here to Login